Among recent megamergers only AbbVie-Allergan looks like a winner: analyst

Why is combining AbbVie and Allergan a good move? AbbVie will benefit from diversifying into a new therapeutic area, aesthetics, Porges suggests. Neither BMS nor Takeda will add any new significant therapeutic areas to their portfolios in doing their respective deals, he said.